Posters single page
- Details
- Written by: web web
- Category: Posters single page
- Hits: 261
Posters single page
AD/PD™ 2024
GT-02287, A CLINICAL STAGE GLUCOCEREBROSIDASE REGULATOR FOR THE TREATMENT OF PD, EASES ER STRESS AND ENHANCES LYSOSOMAL ENZYME ACTIVITY
20th Annual WORLDSymposium®
GT-02287, a clinical stage GCase enhancer, displays neuroprotection and restores motor function in preclinical models of Parkinson’s disease following delayed administration
2023 International Congress of Parkinson's Disease and Movement Disorders®
GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase shows evidence of pharmacological efficacy in an animal model of Parkinson’s disease
2023 International Congress of Parkinson's Disease and Movement Disorders®
Neuroprotective effect of GT-02287, a brain-penetrant structurally targeted allosteric regulator of glucocerebrosidase, leads to a significant reduction of plasma NfL levels and improvement in behavioural deficits in a mouse model of GBA1 Parkinson’s dise
2023 Gordon Research Conference on Lysosomal Diseases
Identification of novel allosteric β-galactosidase regulators that prevent GM1 ganglioside accumulation
Scientific Conference: AD/PD 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and...
Small-Molecule Structurally Targeted Allosteric Regulators Of Glucocerebrosidase Show Neuroprotective Properties In Cell-Based Models Of Alzheimer’s Disease
19th annual WORLDSymposium (2023)
GT-02329, a structurally targeted allosteric regulator of GCase, restores GCase activity, reduces microgliosis and improves fine locomotor skills in the CBE model of neuronopathic Gaucher’s disease
2022 SYNUCLEIN MEETING
Targeting glucocerebrosidase with structurally targeted allosteric regulators corrects abnormal phenotypes in models of Parkinson’s disease
International Congress of Parkinson’s Disease and Movement Disorders 2022 Annual Meeting
GT-02287, A Brain-penetrant Structurally Targeted Allosteric Regulator of Glucocerebrosidase Shows Evidence of Pharmacological Efficacy in Conduritol β-epoxide (CBE) Models of Parkinson’s Disease
XXVII World Congress on Parkinson’s Disease and Related Disorders
GT-02287, a Brain-Penetrant Structurally Targeted Allosteric Regulator for Glucocerebrosidase Shows Evidence of Pharmacological Efficacy in Models of Parkinson’s Disease
2022 GLYCOLIPID AND SPHINGOLIPID BIOLOGY GRC
Structurally targeted allosteric regulators show promising therapeutic effect in Gaucher Disease cortical neurons
AD/PD™ 2022 International Conference on Alzheimer's and Parkinson's Diseases
Brain-penetrant structurally targeted allosteric regulators for glucocerebrosidase (GCase) show promising pharmacological activity in models of neurodegenerative diseases
18th Annual WORLDSymposium (2022)
Development of structurally targeted allosteric regulators for the treatment of neuronopathic Gaucher disease
World Congress on Parkinson’s Disease and Related Disorders 2021
Preclinical development of brain-penetrant structurally targeted allosteric regulators for the treatment of GBA1 Parkinson’s disease and related alpha-synucleopathies
WORLDSymposium 2021
Insights into the mechanism of action of structurally targeted allosteric regulators for the treatment of Gaucher disease
WORLDSymposium 2021
Preclinical development of brain-penetrant structurally targeted allosteric regulators for the treatment of neuronopathic Gaucher disease
WORLDSymposium 2021
Insights into the mechanism of action of structurally targeted allosteric regulators for the treatment of GLB1-related disorders
Keystone Symposia 2020 - Brain Therapeutics
Correcting protein misfolding with Structurally Targeted Allosteric Regulators: Applications in rare diseases and brain therapeutics
WorldSymposium 2020
Allosteric regulators improving biodistribution of recombinant laronidase in Mucopolysaccharidosis type 1 (MPS1)